Two patients with advanced stage III ovarian cancer had complete regressions after intensive therapy with thiotepa and methotrexate. Both patients showed unusual sensitivity while on maintenance doses of thiotepa. Marrow hypoplasia occurred for several years before gradual development of myeloblastic leukemia, five years after apparent cure of the ovarian neoplasm. These two patients represent 15% of a group of 14 patients surviving five years without clinical recurrence among a total of 400 ovarian cancers treated with chemotherapy since 1959.
(JAMA 230:418-423, 1974